戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 the absence of other risk factors, including polydrug abuse, hypertension, or cerebrovascular disease
2 cts of cocaine, ruling out confounds such as polydrug abuse, preexisting differences in DAT levels, o
3 ce sustained cocaine abstinence in injecting polydrug abusers.
4                  These findings confirm that polydrug-abusing individuals can provide behavioral data
5 fects of nicotine alone and nicotine+cocaine polydrug combinations in a nonhuman primate model of dru
6 eatment of coexisting heroin and amphetamine polydrug dependence in 100 heroin- and amphetamine-depen
7 e pharmacological treatment for this type of polydrug dependence.
8             The majority of drug addicts are polydrug dependent, and no effective pharmacological tre
9 creases in overdose (OD) mortality caused by polydrug exposure to synthetic opioids such as fentanyl
10 can marigold (Tagetes lucida) in presumptive polydrug mixtures.
11 n 2024 versus 2023 were similar to those for polydrug OD (-42% and -39% APC in males and females, res
12 oint regressions detected increases in these polydrug OD after 2018, then decreases from 2023 in male
13 pioids in this time period, the decreases in polydrug OD mortality are more likely to be caused by ch
14                            Males had greater polydrug OD mortality caused by synthetic opioids and st
15 icate that after increases from 2018 onward, polydrug OD mortality caused by synthetic opioids and st
16                                   While this polydrug OD mortality has decreased in 2024, it remains
17                          Recent decreases in polydrug OD mortality were observed across age groups, w
18  to understand the recent trajectory in this polydrug OD mortality, especially as associated with dec
19   Stratification into 10-year age groups for polydrug OD revealed that mortality peaked at age 35-44
20                                    For these polydrug OD, the mean annual percent change (APC) in 202
21  among groups of individuals using ketamine, polydrugs or smoking cigarette.
22  100 000 person-years), including opioid and polydrug overdoses, and homicide deaths (-23 per 100 000
23 nal drug overdoses, unintentional opioid and polydrug overdoses, suicides, and homicides.
24  in cocaine abuse patients is complicated by polydrug use and other comorbid factors, hindering the d
25 (F10.X), cannabis use disorders (F12.X), and polydrug use disorders (F19.X).
26 We observed similar patterns for alcohol and polydrug use disorders, separately, although differences
27  the prevalence of recreational drug use and polydrug use in the previous 3 months and associations w
28                            Deaths related to polydrug use increased from 23.2% in 2011 to 30.6% in 20
29                                              Polydrug use is prevalent in HIV-diagnosed MSM and is st
30                                   Increasing polydrug use was associated with increasing prevalence o
31               We examined the association of polydrug use with measures of condomless sex in the prev
32 nts and mothers were screened for cocaine or polydrug use.
33                Individuals with ketamine and polydrugs use have significantly worse drug-related prob
34                                              Polydrug users and users who tested positive for the use
35              Sixteen control subjects and 16 polydrug users reporting MA as their primary drug of abu
36 smokers and ketamine users, individuals with polydrug users scored significantly higher on impulsivit
37 ceptor, might be upregulated in brains of MA polydrug users, although lower dopamine levels in MA use
38 ding is above normal in methamphetamine (MA) polydrug users, using PET and the D3-preferring ligand [